Sp902
A SURGEON’S GUIDE FOR UNDERSTANDING AND MANAGING PERIANAL FISTULAS
Date
May 8, 2023
Explore related products in the following collection:
Society: AGA
Management of diseases of the ileo-anal pouch and perianal Crohn’s disease is challenging and involves multidisciplinary medical and surgical care. This session review the contemporary management of these complex clinical situations. It will also update the clinician and researcher on the emerging concepts of fibrosis as a therapeutic target as well as aging and frailty in in the management of IBD.
Management of diseases of the ileo-anal pouch and perianal Crohn’s disease is challenging and involves multidisciplinary medical and surgical care. This session review the contemporary management of these complex clinical situations. It will also update the clinician and researcher on the emerging concepts of fibrosis as a therapeutic target as well as aging and frailty in in the management of IBD.
Presenter
Cleveland Clinic
Tracks
Related Products
HABITUAL MEAT INTAKE IS ASSOCIATED WITH INCREASED RISK OF DISEASE FLARE IN ULCERATIVE COLITIS: INITIAL RESULTS FROM THE PREDICCT STUDY
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PRA023 AS INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: ARTEMIS-UC, COHORT 1
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
